Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4740611 | 1.00 | GAA (0.35) | GAAMGAMPDK1PDK2PDK3 | |
| SCHEMBL23206546 | 1.00 | GAA (0.35) | GAAMGAMPDK1PDK2PDK3 | |
| SCHEMBL13634386 | 1.00 | GAA (0.35) | GAAMGAMPDK1PDK2PDK3 | |
| SCHEMBL25668004 | 1.00 | GAA (0.35) | GAAMGAMPDK1PDK2PDK3 | |
| SCHEMBL25551655 | 0.82 | GAA (0.34) | GAAMGAMTP53CYP3A4ALOX15 | |
| SCHEMBL23158050 | 0.82 | GAA (0.34) | GAAMGAMTP53CYP3A4ALOX15 | |
| SCHEMBL26059860 | 0.80 | PDK1 (0.36) | GAAMGAMPDK1TP53CYP3A4 | |
| SCHEMBL23178981 | 0.80 | PDK1 (0.36) | GAAMGAMPDK1TP53CYP3A4 | |
| SCHEMBL23640636 | 0.79 | GAA (0.32) | GAAMGAM | |
| SCHEMBL22349101 | 0.79 | ALDH1A1 (0.39) | GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389751-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023215802-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215801-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023141300-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230174526-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | SHANGHAI RINGENE THERAPEUTICS CO. LTD (CN) | 2023-06-08 | — | — | US | disclosed |
| WO-2023086383-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | 1200 PHARMA LLC (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023274383-A1 | KRAS G12D INHIBITOR AND USE THEREOF | 上海迪诺医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022266015-A1 | FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS | KUMQUAT BIOSCIENCES INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022047260-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021218110-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | 上海凌达生物医药有限公司 | 2021-11-04 | — | — | WO | disclosed |
| WO-2021063346-A1 | KRAS G12C INHIBITOR AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| US-20160354476-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354476-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | FUT6, GALNT6, FUT5 | GAA 106/4885MGAM 730/4885PDK1 1909/4885 |
| US-20230174526-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | KRAS, NRAS, HRAS | GAA 1832/4885MGAM 3471/4885PDK1 1335/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | GAA 3036/4885MGAM 4298/4885PDK1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.